Latest News and Press Releases

2Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus 2Q 20172Q 2018 Afrezza TRx grew 71% versus 2Q 2017Debt principal reduced by $42.6 million, or 27%, year-to-dateSuccessfully completed...

WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 second quarter and year-to-date financial results and...

WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

Oral presentation (348-OR) at 5:00 pm today Afrezza provides greater improvement in post-prandial glucose control than insulin aspart WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) --...

Poster 1017-P:  Afrezza provides improved Time-in-Range on Continuous Glucose Monitoring compared to insulin aspart Poster 102-LB:  Hypoglycemia is reduced with use of Afrezza compared to insulin...

Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes...

Study achieved primary endpoint of safety and tolerabilityProgressive dosing of Treprostinil Technosphere (TreT) significantly exceeded the corresponding peak plasma and exposure levels of the maximum...

WESTLAKE VILLAGE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a...

Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model)Q1 2018 Net Cash Used in Operating Activities was $21.7 millionSTAT study results...